BITPRISMIA
Nasdaq-listed biotech firm 180 Life Sciences, operating as ETHZilla, has invested $349 million in Ethereum, signaling a significant move into the cryptocurrency space and highlighting corporate crypto adoption.
180 Life Sciences, a biotechnology company, has secured $425 million in private investment primarily for a significant Ethereum (ETH) purchase, signaling a strategic shift towards leveraging blockchain technology for various operations.
180 Life Sciences is shifting its focus to Ethereum by raising $425 million through a PIPE transaction to acquire ETH for its corporate treasury and rebranding as ETHZilla Corporation, signaling a significant corporate embrace of cryptocurrency.
Nasdaq-listed biotech firm Windtree Therapeutics plans to raise $520 million for a strategic BNB acquisition, signaling a significant cross-industry investment between biotech and cryptocurrency.
Latent Labs has launched a web-based AI for protein design, backed by $50 million in funding, aiming to democratize biology and accelerate drug discovery by enabling the creation of novel proteins.
A Stanford University study highlights significant risks and stigmatization issues associated with AI therapy chatbots, emphasizing the need for critical evaluation and guidelines in their use for mental health support.
Changpeng Zhao (CZ), founder of Binance, donated $10 million in BNB to Vitalik Buterin's biotech initiative, highlighting crypto philanthropy's role in supporting open-source biotech and human health.